(S)-2-((3S,6R,9S,12S,15S,18R,23R,26S,29S,34aS,37R)-37-(2-aminoacetamido)-29-(carboxymethyl)-3,15-bis(3-guanidinopropyl)-12-(4-hydroxybenzyl)-26-(hydroxymethyl)-1,4,7,10,13,16,24,27,30,36-decaoxo-9-(3-ureidopropyl)dotriacontahydro-23,6-(epiminopropanodithiomethano)pyrrolo[2,1-v][1,2,5,8,11,14,17,20,23,26,29]dithianonaazacyclodotriacontine-18-carboxamido)-5-guanidinopentanoic acid

ID: ALA5220778

Chembl Id: CHEMBL5220778

PubChem CID: 168299482

Max Phase: Preclinical

Molecular Formula: C59H94N24O19S4

Molecular Weight: 1571.82

Names and Identifiers

Canonical SMILES:  N=C(N)NCCC[C@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CCCNC(N)=O)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)O

Standard InChI:  InChI=1S/C59H94N24O19S4/c60-22-42(86)72-37-24-103-104-25-38-50(95)74-30(8-3-18-71-59(67)102)44(89)77-34(20-28-11-13-29(85)14-12-28)47(92)73-31(6-1-15-68-56(61)62)45(90)81-39(51(96)76-33(55(100)101)9-4-17-70-58(65)66)26-105-106-27-40(82-49(37)94)52(97)79-36(23-84)48(93)78-35(21-43(87)88)54(99)83-19-5-10-41(83)53(98)75-32(46(91)80-38)7-2-16-69-57(63)64/h11-14,30-41,84-85H,1-10,15-27,60H2,(H,72,86)(H,73,92)(H,74,95)(H,75,98)(H,76,96)(H,77,89)(H,78,93)(H,79,97)(H,80,91)(H,81,90)(H,82,94)(H,87,88)(H,100,101)(H4,61,62,68)(H4,63,64,69)(H4,65,66,70)(H3,67,71,102)/t30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-/m0/s1

Standard InChI Key:  BNNGAADQWHAZEM-VFWMWCIBSA-N

Alternative Forms

1. Parent:

   

   ALA5220778

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 1571.82

Molecular Weight (Monoisotopic): 1570.6010

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Gajewiak J, Christensen SB, Dowell C, Hararah F, Fisher F, Huynh PN, Olivera BM, McIntosh JM..  (2021)  Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism.,  64  (13.0): [PMID:34142837] [10.1021/acs.jmedchem.1c00512]

Source

Source(1):

• Scientific Literature